These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11550952)

  • 1. A simple algorithm for designing group sequential clinical trials.
    Schoenfeld DA
    Biometrics; 2001 Sep; 57(3):972-4. PubMed ID: 11550952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A computationally simpler algorithm for the UMVUE of a normal mean following a group sequential trial.
    Emerson SS; Kittelson JM
    Biometrics; 1997 Mar; 53(1):365-9. PubMed ID: 9147601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choice of futility boundaries for group sequential designs with two endpoints.
    Schüler S; Kieser M; Rauch G
    BMC Med Res Methodol; 2017 Aug; 17(1):119. PubMed ID: 28789615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The type II error probability of a group sequential test of efficacy and futility, and considerations for power and sample size.
    Dobbins TW
    J Biopharm Stat; 2013 Mar; 23(2):378-93. PubMed ID: 23437945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal adaptive designs for binary response trials.
    Rosenberger WF; Stallard N; Ivanova A; Harper CN; Ricks ML
    Biometrics; 2001 Sep; 57(3):909-13. PubMed ID: 11550944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of sample size in group sequential clinical trials.
    Cui L; Hung HM; Wang SJ
    Biometrics; 1999 Sep; 55(3):853-7. PubMed ID: 11315017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential approaches.
    Müller HH; Schäfer H
    Biometrics; 2001 Sep; 57(3):886-91. PubMed ID: 11550941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Closed testing procedures for group sequential clinical trials with multiple endpoints.
    Tang DI; Geller NL
    Biometrics; 1999 Dec; 55(4):1188-92. PubMed ID: 11315066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive probability in clinical trials.
    Grieve AP
    Biometrics; 1991 Mar; 47(1):323-9; discussion 330. PubMed ID: 2049506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints.
    Asakura K; Hamasaki T; Evans SR
    Biom J; 2017 Jul; 59(4):703-731. PubMed ID: 27757980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the timing of a futility analysis in clinical trials.
    Pallay A
    J Biopharm Stat; 2000 Aug; 10(3):399-405. PubMed ID: 10959919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive vs. group sequential self-designing trials.
    Mehrotra DV; Fan X
    Biom J; 2006 Aug; 48(4):710-2; discussion 713. PubMed ID: 16972723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Group sequential designs for monitoring survival probabilities.
    Lin DY; Shen L; Ying Z; Breslow NE
    Biometrics; 1996 Sep; 52(3):1033-41. PubMed ID: 8805766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ketoconazole to prevent acute respiratory distress syndrome in critically ill patients.
    Frazee LA; Neidig JA
    Ann Pharmacother; 1995; 29(7-8):784-6. PubMed ID: 8520099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of a parameter and its exact confidence interval following sequential sample size reestimation trials.
    Cheng Y; Shen Y
    Biometrics; 2004 Dec; 60(4):910-8. PubMed ID: 15606411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of methods for futility stopping based on conditional power.
    Lachin JM
    Stat Med; 2005 Sep; 24(18):2747-64. PubMed ID: 16134130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and monitoring of multi-arm multi-stage clinical trials.
    Ghosh P; Liu L; Senchaudhuri P; Gao P; Mehta C
    Biometrics; 2017 Dec; 73(4):1289-1299. PubMed ID: 28346823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computation of the uniform minimum variance unbiased estimator of a normal mean following a group sequential trial.
    Emerson SS
    Comput Biomed Res; 1993 Feb; 26(1):68-73. PubMed ID: 8444028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal Futility Interim Design: A Predictive Probability of Success Approach with Time-to-Event Endpoint.
    Tang Z
    J Biopharm Stat; 2015; 25(6):1312-9. PubMed ID: 25379701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and analysis of group sequential logrank tests in maximum duration versus information trials.
    Kim K; Boucher H; Tsiatis AA
    Biometrics; 1995 Sep; 51(3):988-1000. PubMed ID: 7548714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.